脓毒症生物标志物研究进展
Research Progress in Biomarkers of Sepsis
DOI: 10.12677/ACM.2023.134752, PDF,   
作者: 敖玉培, 胡怀东*:重庆医科大学附属第二医院,重庆
关键词: 脓毒症生物标志物Sepsis Biomarkers
摘要: 脓毒症目前定义为由宿主对感染的免疫反应失调引起的危及生命的器官功能障碍,通常可归因于细菌感染,但病毒、真菌或寄生虫引起的感染也可能导致脓毒症。如果不及早发现并及时处理,可能导致感染性休克、多器官衰竭和死亡。据统计,脓毒症发病率及死亡率极高,是重症医学科危重症患者死亡的主要原因,且对于幸存者,也导致生活质量严重下降。因此,及时诊断及治疗脓毒症,成为医疗卫生工作的重点。但目前尚无法建立金标准或有效的指标来明确识别脓毒症患者。近年来,关于脓毒症相关生物标志物的研究取得了较大的进展,对脓毒症的早期识别有着较高的灵敏性和特异性。本项研究就几种生物标志物在感染及脓毒症的发生、发展中的研究进展进行阐述。
Abstract: Sepsis is currently defined as life-threatening organ dysfunction caused by dysregulation of the host’s immune response to infection and can often be attributed to bacterial infection, but infections caused by viruses, fungus, or parasites can also cause sepsis. If not detected early and treated promptly, it will lead to septic shock, multiple organ failure, and death. According to statistics, the incidence and mortality of sepsis are extremely high, which is the main cause of death for critically ill patients in the Department of Intensive Care Medicine, and for survivors, it also leads to a serious decline in the quality of life. Therefore, timely diagnosis and treatment of sepsis has become the focus of medical and health work. However, there is currently no gold standard or effective indicator to clearly identify patients with sepsis. In recent years, great progress has been made in the research on sepsis-related biomarkers, and it has high sensitivity and specificity for the early recognition of sepsis. This study describes the research progress of several biomarkers in the occurrence and development of infection and sepsis.
文章引用:敖玉培, 胡怀东. 脓毒症生物标志物研究进展[J]. 临床医学进展, 2023, 13(4): 5312-5317. https://doi.org/10.12677/ACM.2023.134752

参考文献

[1] Vincent, J.L., Martinez, E.O. and Silva, E. (2011) Evolving Concepts in Sepsis Definitions. Critical Care Nursing Clin-ics of North America, 23, 29-39. [Google Scholar] [CrossRef] [PubMed]
[2] Liu, A.C., Patel, K., Vunikili, R.D., et al. (2020) Sepsis in the Era of Data-Driven Medicine: Personalizing Risks, Diagnoses, Treatments and Progno-ses. Briefings in Bioinformatics, 21, 1182-1195. [Google Scholar] [CrossRef] [PubMed]
[3] Cecconi, M., Evans, L., Levy, M., et al. (2018) Sepsis and Septic Shock. The Lancet, 392, 75-87. [Google Scholar] [CrossRef
[4] Pant, A., Mackraj, I. and Govender, T. (2021) Advances in Sepsis Diagnosis and Management: A Paradigm Shift towards Nanotechnology. Journal of Biomedical Science, 28, 6. [Google Scholar] [CrossRef] [PubMed]
[5] Berry, M., Patel, B.V. and Brett, S.J. (2017) New Consensus Definitions for Sepsis and Septic Shock: Implications for Treatment Strategies and Drug Development? Drugs, 77, 353-361. [Google Scholar] [CrossRef] [PubMed]
[6] Tidswell, R., Inada-Kim, M. and Singer, M. (2021) Sepsis: The Importance of an Accurate Final Diagnosis. The Lancet Respiratory Medicine, 9, 17-18. [Google Scholar] [CrossRef
[7] Lippi, G. (2019) Sepsis Biomarkers: Past, Present and Future. Clinical Chemistry and Laboratory Medicine, 57, 1281- 1283. [Google Scholar] [CrossRef] [PubMed]
[8] Pierrakos, C. and Vincent, J.L. (2010) Sepsis Biomarkers: A Review. Critical Care, 14, R15. [Google Scholar] [CrossRef] [PubMed]
[9] Fisher, J. and Linder, A. (2017) Heparin-Binding Protein: A Key Player in the Pathophysiology of Organ Dysfunction in Sepsis. Journal of Internal Medicine, 281, 562-574. [Google Scholar] [CrossRef] [PubMed]
[10] Lin, G.C., Kung, E., Smajlhodzic, M., et al. (2021) Directed Transport of CRP across in Vitro Models of the Blood- Saliva Barrier Strengthens the Feasibility of Salivary CRP as Biomarker for Neonatal Sepsis. Pharmaceutics, 13, 256. [Google Scholar] [CrossRef] [PubMed]
[11] Tang, Y., Ling, N., Li, S., et al. (2021) A Panel of Urine-Derived Biomarkers to Identify Sepsis and Distinguish It from Systemic Inflammatory Response Syndrome. Sci-entific Reports, 11, 20794. [Google Scholar] [CrossRef] [PubMed]
[12] Raeven, P., Zipperle, J. and Drechsler, S. (2018) Extracellular Vesicles as Markers and Mediators in Sepsis. Theranostics, 8, 3348-3365. [Google Scholar] [CrossRef] [PubMed]
[13] Cao, X.E., Ongagna-Yhombi, S.Y., Wang, R., et al. (2022) A Diagnostic Platform for Rapid, Simultaneous Quantification of Procalcitonin and C-Reactive Protein in Human Serum. EBioMedicine, 76, 103867. [Google Scholar] [CrossRef] [PubMed]
[14] Lee, E.H., Lee, K.H., Song, Y.G., et al. (2022) Discrepancy of C-Reactive Protein, Procalcitonin and Interleukin-6 at Hospitalization: Infection in Patients with Normal C-Reactive Pro-tein, Procalcitonin and High Interleukin-6 Values. Journal of Clinical Medicine, 11, 7324. [Google Scholar] [CrossRef] [PubMed]
[15] Rajab, I.M., Hart, P.C. and Potempa, L.A. (2020) How C-Reactive Pro-tein Structural Isoforms with Distinctive Bioactivities Affect Disease Progression. Frontiers in Immunology, 11, 2126. [Google Scholar] [CrossRef] [PubMed]
[16] Castelli, G.P., Pognani, C., Meisner, M., et al. (2004) Procalcitonin and C-Reactive Protein during Systemic Inflammatory Response Syndrome, Sepsis and Organ Dysfunction. Critical Care, 8, R234-R242. [Google Scholar] [CrossRef] [PubMed]
[17] Hofer, N., Zacharias, E., Müller, W., et al. (2012) An Update on the Use of C-Reactive Protein in Early-Onset Neonatal Sepsis: Current Insights and New Tasks. Neonatology, 102, 25-36. [Google Scholar] [CrossRef] [PubMed]
[18] Mac Giollabhui, N., Ellman, L.M., Coe, C.L., et al. (2020) To Exclude or Not to Exclude: Considerations and Recommendations for C-Reactive Protein Values Higher than 10 mg/L. Brain, Be-havior, and Immunity, 87, 898-900. [Google Scholar] [CrossRef] [PubMed]
[19] Ruan, L., Chen, G.Y., Liu, Z., et al. (2018) The Combination of Procalcitonin and C-Reactive Protein or Presepsin Alone Improves the Accuracy of Diagnosis of Neonatal Sepsis: A Meta-Analysis and Systematic Review. Critical Care, 22, 316. [Google Scholar] [CrossRef] [PubMed]
[20] Kyriazopoulou, E., Poulakou, G. and Giamarellos-Bourboulis, E.J. (2021) Biomarkers in Sepsis: Can They Help Improve Patient Outcome? Current Opinion in Infectious Diseases, 34, 126-134. [Google Scholar] [CrossRef
[21] Kyriazopoulou, E., Liaskou-Antoniou, L., Adamis, G., et al. (2021) Procalcitonin to Reduce Long-Term Infection-Associated Adverse Events in Sepsis. A Randomized Trial. Ameri-can Journal of Respiratory and Critical Care Medicine, 203, 202-210. [Google Scholar] [CrossRef
[22] Wacker, C., Prkno, A., Brunkhorst, F.M., et al. (2013) Procal-citonin as a Diagnostic Marker for Sepsis: A Systematic Review and Meta-Analysis. The Lancet Infectious Diseases, 13, 426-435. [Google Scholar] [CrossRef
[23] Sridharan, P. and Chamberlain, R.S. (2013) The Efficacy of Procalcitonin as a Biomarker in the Management of Sepsis: Slaying Dragons or Tilting at Windmills? Surgical Infections (Larchmt), 14, 489-511. [Google Scholar] [CrossRef] [PubMed]
[24] Rashwan, N.I., Hassan, M.H., Mohey El-Deen, Z.M., et al. (2019) Va-lidity of Biomarkers in Screening for Neonatal Sepsis—A Single Center-Hospital Based Study. Pediatrics & Neonatolo-gy, 60, 149-155. [Google Scholar] [CrossRef] [PubMed]
[25] Stocker, M., Van Herk, W., El Helou, S., et al. (2021) C-Reactive Protein, Procalcitonin, and White Blood Count to Rule Out Neonatal Early-Onset Sepsis within 36 Hours: A Secondary Analysis of the Neonatal Procalcitonin Intervention Study. Clinical Infectious Diseases, 73, e383-e390. [Google Scholar] [CrossRef] [PubMed]
[26] Mantovani, A., Garlanda, C., Doni, A., et al. (2008) Pentraxins in Innate Immunity: From C-Reactive Protein to the Long Pentraxin PTX3. Journal of Clinical Immunology, 28, 1-13. [Google Scholar] [CrossRef] [PubMed]
[27] Hamed, S., Behnes, M., Pauly, D., et al. (2017) Diagnostic Value of Pentraxin-3 in Patients with Sepsis and Septic Shock in Accordance with Latest Sepsis-3 Definitions. BMC Infectious Diseases, 17, 554. [Google Scholar] [CrossRef] [PubMed]
[28] Lee, Y.T., Gong, M., Chau, A., et al. (2018) Pentraxin-3 as a Marker of Sepsis Severity and Predictor of Mortality Outcomes: A Systematic Review and Meta-Analysis. Journal of Infection, 76, 1-10. [Google Scholar] [CrossRef] [PubMed]
[29] Wang, C., Liang, G., Shen, J., et al. (2021) Long Non-Coding RNAs as Biomarkers and Therapeutic Targets in Sepsis. Frontiers in Immunology, 12, Article ID: 722004. [Google Scholar] [CrossRef] [PubMed]
[30] Hashemian, S.M., Pourhanifeh, M.H., Fadaei, S., et al. (2020) Non-Coding RNAs and Exosomes: Their Role in the Pathogenesis of Sepsis. Molecular Therapy—Nucleic Acids, 21, 51-74. [Google Scholar] [CrossRef] [PubMed]
[31] Ghafouri-Fard, S., Khoshbakht, T., Hussen, B.M., et al. (2021) Regulatory Role of Non-Coding RNAs on Immune Responses during Sepsis. Frontiers in Immunology, 12, Ar-ticle ID: 798713. [Google Scholar] [CrossRef] [PubMed]
[32] Wang, W., Yang, N., Wen, R., et al. (2021) Long Noncoding RNA: Regulatory Mechanisms and Therapeutic Potential in Sepsis. Frontiers in Cellular and Infection Microbiology, 11, Article ID: 563126. [Google Scholar] [CrossRef] [PubMed]
[33] Beltrán-García, J., Osca-Verdegal, R., Nácher-Sendra, E., et al. (2021) Role of Non-Coding RNAs as Biomarkers of Deleterious Cardiovascular Effects in Sepsis. Progress in Cardio-vascular Diseases, 68, 70-77. [Google Scholar] [CrossRef] [PubMed]
[34] Liu, W., Geng, F. and Yu, L. (2020) Long Non-Coding RNA MALAT1/microRNA 125a Axis Presents Excellent Value in Discriminating Sepsis Patients and Exhibits Positive Asso-ciation with General Disease Severity, Organ Injury, Inflammation Level, and Mortality in Sepsis Patients. Journal of Clinical Laboratory Analysis, 34, e23222. [Google Scholar] [CrossRef] [PubMed]
[35] Li, J., Zhang, Y., Zhang, D., et al. (2021) The Role of Long Non-Coding RNAs in Sepsis-Induced Cardiac Dysfunction. Frontiers in Cardiovascular Medicine, 8, Article ID: 684348. [Google Scholar] [CrossRef] [PubMed]
[36] Piva, E., Zuin, J., Pelloso, M., et al. (2021) Monocyte Distribution width (MDW) Parameter as a Sepsis Indicator in Intensive Care Units. Clinical Chemistry and Laboratory Medicine, 59, 1307-1314. [Google Scholar] [CrossRef] [PubMed]
[37] Hausfater, P., Robert, B.N., Morales, I.C., et al. (2021) Monocyte Distribution width (MDW) Performance as an Early Sepsis Indicator in the Emergency Department: Comparison with CRP and Procalcitonin in a Multicenter International European Prospective Study. Critical Care, 25, 227. [Google Scholar] [CrossRef] [PubMed]
[38] Crouser, E.D., Parrillo, J.E., Martin, G.S., et al. (2020) Mono-cyte Distribution Width Enhances Early Sepsis Detection in the Emergency Department beyond SIRS and qSOFA. Journal of Intensive Care, 8, 33. [Google Scholar] [CrossRef] [PubMed]
[39] Jo, S.J., Kim, S.W., Choi, J.H., et al. (2022) Monocyte Distribu-tion Width (MDW) as a Useful Indicator for Early Screening of Sepsis and Discriminating False Positive Blood Cultures. PLOS ONE, 17, e0279374. [Google Scholar] [CrossRef] [PubMed]